Designed to provide broad exposure to the Healthcare - Biotech segment of the equity market, the iShares Biotechnology ETF (IBB) is a passively managed exchange traded fund launched on February 5, ...

Raise large amounts of capital with an initial public offering, burn cash while navigating clinical trials, then submit a new ...

Amid the trying circumstances in the market right now, investors may be well served to target the best biotech ETFs to buy. Fundamentally, these exchange-traded funds benefit from permanent relevance.

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. When it comes to biotech ETFs, they give sector participants exposure to many biotech companies via one ...

Biotech ETFs have had a banner year, earning some investors returns north of 30 percent since January. I say “some investors” because, it turns out, not all biotech ETFs are created equal. In our 2012 ...

This was a new position; the IBB stake now accounts for 8.7% of Florin Court Capital LLP’s 13F AUM ICLN: $16.6 million (13.0% of AUM) IBB: $11.1 million (8.7% of AUM) IVW: $11.0 million (8.6% of AUM) ...

The iShares Biotechnology ETF is up over 32% in six months on rate cut expectations and potential sector rotation. The State Street SPDR S&P Biotech ETF has surged 45% in six months but remains 27% ...

Biotech-based exchange-traded fund (ETF) iShares Biotechnology ETF IBB has rallied 26.1% over the past six months (as of Oct. 27, 2025), outperforming SPDR S&P 500 ETF Trust SPY (up 24.4%). Year to ...

The iShares Biotechnology ETF offers diversified exposure to the biotech sector, focusing on large-cap leaders while maintaining positions in smaller innovators. IBB is cap-weighted and top-heavy, ...

When it comes to discussing the best ETFs to buy in 2026, the discussion usually starts with tech and artificial intelligence ...

This rally in Illumina proved a shot in the arm for one of the most Illumina-sensitive funds, the ARK Genomic Revolution ETF (BATS:ARKG). It surged about 4% this week to outperform broader biotech ...